Vancity Investment Management Ltd Grows Position in Edwards Lifesciences Corporation $EW

Posted by Brian Himes on Sep 7th, 2026

Vancity Investment Management Ltd raised its holdings in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 15.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 167,876 shares of the medical research company’s stock after acquiring an additional 22,881 shares during the quarter. Edwards Lifesciences accounts for about 2.3% of Vancity Investment Management Ltd’s holdings, making the stock its 15th biggest position. Vancity Investment Management Ltd’s holdings in Edwards Lifesciences were worth $15,186,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in EW. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth about $25,000. Hanson & Doremus Investment Management acquired a new stake in shares of Edwards Lifesciences during the 1st quarter valued at approximately $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at approximately $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $26,000. Finally, Pin Oak Investment Advisors Inc. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $26,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,045 shares of company stock valued at $457,749 over the last 90 days. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on EW shares. Evercore reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. BTIG Research lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Finally, Mizuho lifted their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Read Our Latest Report on EW

Edwards Lifesciences Stock Up 0.1%

Shares of NYSE:EW opened at $90.00 on Monday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $51.82 billion, a P/E ratio of 51.72, a P/E/G ratio of 2.36 and a beta of 0.85. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The stock’s fifty day simple moving average is $89.73 and its 200-day simple moving average is $85.56.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.